In this article, we will look at the 10 Best 52-Week Low NYSE Stocks to Buy Now.
Stocks hitting 52-week lows tend to draw attention when fear and price action start to outrun fundamentals. Broad selling pressure, geopolitical tension, and shifting macro expectations have pushed more names toward fresh lows, yet not all of them are there for the same reason. While some are dealing with real business deterioration. Others may simply be caught in a broader risk-off move that has dragged down even fundamentally solid companies.
In its 2026 Long-Term Capital Market Assumptions Report, J.P. Morgan notes that “the starting point for valuations has an impact on long-term returns.” The idea fits with 52-week-low investing, since a stock trading near the bottom of its annual range may offer a more favorable setup if the underlying business remains intact. Fidelity makes a similar point in its viewpoint article What to do when stocks drop, saying that “pullbacks can present an opportunity.” Both firms are suggesting that price declines can improve future return potential, provided investors are selective, identifying fundamentally sound companies to invest in.
With that in mind, we will take a closer look at the 10 Best 52-Week Low NYSE Stocks to Buy Now.
Our Methodology
We used the Finviz screener to identify NYSE-listed stocks trading near their 52-week lows. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. AECOM (NYSE:ACM)
On March 24, 2026, AECOM (NYSE:ACM) was selected by the San Diego Unified School District to continue serving as a prime consultant, providing support services for the district’s capital bond programs. The company said the work includes projects such as new classrooms, safety and security upgrades, and sustainability improvements.
On March 19, 2026, AECOM (NYSE:ACM) was awarded a position on the U.S. Missile Defense Agency’s SHIELD indefinite-delivery/indefinite-quantity contract with a ceiling of $151B, covering a range of services tied to facility modernization.
On March 17, 2026, the company was also selected as part of the ILIOS consortium to provide design and technical services for a GBP 200M tranche of the Spherical Tokamak for Energy Production program, aimed at developing a prototype fusion power plant in the UK, with potential future opportunities of up to GBP 10B.
On March 16, AECOM announced that Newtown Creek CSO Partners, a joint venture including AECOM, was selected by the New York City Department of Environmental Protection to provide construction supervision for a combined sewer overflow storage tunnel project, expected to deliver approximately 3.25 miles of tunnels and up to 50 million gallons of storage capacity.
AECOM (NYSE:ACM) provides infrastructure consulting services to governments and businesses globally.
9. Boston Scientific Corporation (NYSE:BSX)
On March 29, 2026, Boston Scientific Corporation (NYSE:BSX) announced that its CHAMPION-AF clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device versus NOACs for stroke risk reduction in patients with non-valvular atrial fibrillation. The company said the device showed a 45% relative reduction in non-procedural bleeding risk and a 34% reduction when including procedural bleeding, while achieving non-inferiority on the primary efficacy endpoint. Results were presented at the American College of Cardiology’s Annual Scientific Session and published in The New England Journal of Medicine.
On March 26, 2026, Goldman Sachs lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $93 from $98 and maintained a Buy rating, reflecting more moderate growth assumptions and a more risk-adjusted outlook. Goldman Sachs said positive data from CHAMPION-AF and increasing physician and investor confidence could support further upside.
On March 24, 2026, Evercore ISI added Boston Scientific Corporation (NYSE:BSX) to its “Tactical Outperform” list with a $96 price target, citing upcoming data presentations as a potential catalyst.
Boston Scientific Corporation (NYSE:BSX) develops and markets medical devices across MedSurg and Cardiovascular segments globally.
